[{"id":"29889af3-ae43-4e06-bdfc-acec22c139fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT07198867","created_at":"2025-10-04T08:02:56.736Z","updated_at":"2025-10-04T08:02:56.736Z","phase":"Phase 1","brief_title":"A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT07198867","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-09-30"},{"id":"6280dfa5-ede9-4d89-a587-10249cd79abf","acronym":"AGORA-1","url":"https://clinicaltrials.gov/study/NCT05199051","created_at":"2022-01-20T15:53:56.079Z","updated_at":"2025-02-25T14:02:40.845Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML","source_id_and_acronym":"NCT05199051 - AGORA-1","lead_sponsor":"Centre Antoine Lacassagne","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/03/2023","start_date":" 06/03/2023","primary_txt":" Primary completion: 03/15/2027","primary_completion_date":" 03/15/2027","study_txt":" Completion: 03/15/2027","study_completion_date":" 03/15/2027","last_update_posted":"2025-02-19"},{"id":"5a8a1ba9-7750-4d42-886f-26c4d198762e","acronym":"NCI-2018-01812","url":"https://clinicaltrials.gov/study/NCT03672539","created_at":"2021-01-18T18:00:52.647Z","updated_at":"2025-02-25T15:43:12.491Z","phase":"Phase 2","brief_title":"Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT03672539 - NCI-2018-01812","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-10"},{"id":"5adabdf3-1484-4c8e-ac66-a9230e113fb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04915612","created_at":"2021-06-07T15:53:27.598Z","updated_at":"2025-02-25T15:35:05.555Z","phase":"Phase 1","brief_title":"Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04915612","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 05/21/2021","start_date":" 05/21/2021","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-10"},{"id":"2bca17a4-1b77-4b70-bb2a-a5dcd7c531ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672147","created_at":"2023-01-05T14:58:28.476Z","updated_at":"2025-02-25T16:39:33.579Z","phase":"Phase 1","brief_title":"CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05672147","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anti-CD33 CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 12/07/2023","start_date":" 12/07/2023","primary_txt":" Primary completion: 09/03/2028","primary_completion_date":" 09/03/2028","study_txt":" Completion: 09/03/2028","study_completion_date":" 09/03/2028","last_update_posted":"2025-02-06"},{"id":"d2f2a1f1-7bb1-4919-a610-7815b806ac30","acronym":"NCI-2019-01726","url":"https://clinicaltrials.gov/study/NCT03900949","created_at":"2021-01-18T19:12:29.931Z","updated_at":"2024-07-02T16:35:01.958Z","phase":"Phase 1","brief_title":"Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT03900949 - NCI-2019-01726","lead_sponsor":"Uma Borate","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" CD33 positive • CD33 expression","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • midostaurin • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Suspended","enrollment":" Enrollment 18","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-22"},{"id":"7e5df265-735a-4b50-970f-ba82acf13b08","acronym":"","url":"https://clinicaltrials.gov/study/NCT05189639","created_at":"2022-01-12T14:53:46.362Z","updated_at":"2024-07-02T16:35:19.384Z","phase":"","brief_title":"A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05189639","lead_sponsor":"Pfizer","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 12/05/2023","start_date":" 12/05/2023","primary_txt":" Primary completion: 11/17/2027","primary_completion_date":" 11/17/2027","study_txt":" Completion: 11/17/2027","study_completion_date":" 11/17/2027","last_update_posted":"2024-02-14"},{"id":"6a7383f9-1e51-45e9-9cb1-1708edc28ea2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02117297","created_at":"2021-01-18T09:48:00.874Z","updated_at":"2024-07-02T16:35:31.643Z","phase":"Phase 2","brief_title":"SCT Plus Immune Therapy in Average Risk AML/MDS","source_id_and_acronym":"NCT02117297","lead_sponsor":"New York Medical College","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 01/12/2012","start_date":" 01/12/2012","primary_txt":" Primary completion: 03/30/2023","primary_completion_date":" 03/30/2023","study_txt":" Completion: 03/30/2023","study_completion_date":" 03/30/2023","last_update_posted":"2023-10-26"},{"id":"38aa9c92-b86b-4c71-ac1f-a0585bd922fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05987696","created_at":"2023-08-14T15:10:11.648Z","updated_at":"2024-07-02T16:35:40.228Z","phase":"Phase 1","brief_title":"Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia","source_id_and_acronym":"NCT05987696","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive • CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • CD33/CLL1 dual CAR-NK cell • Super NK cell therapy"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-08-11"},{"id":"ea424ad4-9fe1-4d9d-bea7-2fc6acf46bfb","acronym":"VINCENT","url":"https://clinicaltrials.gov/study/NCT05904106","created_at":"2023-06-15T18:09:01.706Z","updated_at":"2024-07-02T16:35:40.488Z","phase":"Phase 2","brief_title":"Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML","source_id_and_acronym":"NCT05904106 - VINCENT","lead_sponsor":"Technische Universität Dresden","biomarkers":" ABL1 • NPM1 • CD33","pipe":" | ","alterations":" NPM1 mutation • CD33 positive","tags":["ABL1 • NPM1 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2023-08-09"},{"id":"8b14bf99-2f4f-4d08-a7e0-83d152f96cb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03867682","created_at":"2021-01-18T19:04:27.493Z","updated_at":"2024-07-02T16:35:41.038Z","phase":"Phase 1/2","brief_title":"Venetoclax and Lintuzumab-Ac225 in AML Patients","source_id_and_acronym":"NCT03867682","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Erbitux (cetuximab) • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-08-04"},{"id":"61649098-7ef6-4a13-80de-89bda601b206","acronym":"","url":"https://clinicaltrials.gov/study/NCT05916443","created_at":"2023-06-23T13:09:24.855Z","updated_at":"2024-07-02T16:35:42.210Z","phase":"","brief_title":"Dissecting the Biology of Early-onset Colorectal Cancer","source_id_and_acronym":"NCT05916443","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" CD44 • CD24","pipe":" | ","alterations":" CD33 positive • CD44 expression • CD133 positive","tags":["CD44 • CD24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD44 expression • CD133 positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-07-24"},{"id":"38d70ca6-e60e-428e-839b-b4649d1ec035","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932318","created_at":"2021-01-18T19:22:10.225Z","updated_at":"2024-07-02T16:35:42.415Z","phase":"Phase 1/2","brief_title":"Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients","source_id_and_acronym":"NCT03932318","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Erbitux (cetuximab) • azacitidine • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-07-20"},{"id":"a7cfcc21-cc8b-4a64-9046-59fd8a1f40d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02575963","created_at":"2021-01-18T12:29:18.783Z","updated_at":"2024-07-02T16:35:42.400Z","phase":"Phase 1/2","brief_title":"Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients","source_id_and_acronym":"NCT02575963","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cytarabine • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2023-07-20"},{"id":"2ed79be2-2023-4696-88ba-ba835e740c51","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005962","created_at":"2021-01-17T23:52:00.807Z","updated_at":"2024-07-02T16:35:45.247Z","phase":"Phase 2","brief_title":"Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia","source_id_and_acronym":"NCT00005962","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • topotecan • Leukine (sargramostim)"],"overall_status":"Completed","enrollment":"","initiation":"Initiation: 10/04/2000","start_date":" 10/04/2000","primary_txt":" Primary completion: 10/01/2005","primary_completion_date":" 10/01/2005","study_txt":" Completion: 06/01/2007","study_completion_date":" 06/01/2007","last_update_posted":"2023-06-22"},{"id":"da225a45-4246-4e90-a4b5-d01c0f7dff7e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04835519","created_at":"2021-04-08T13:52:32.724Z","updated_at":"2024-07-02T16:35:56.172Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04835519","lead_sponsor":"Beijing Boren Hospital","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD33 CAR T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 09/08/2024","primary_completion_date":" 09/08/2024","study_txt":" Completion: 09/08/2024","study_completion_date":" 09/08/2024","last_update_posted":"2023-02-08"},{"id":"9bd42bb7-1fd2-4126-995e-0c74a47e0e47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05665075","created_at":"2022-12-27T15:59:02.163Z","updated_at":"2024-07-02T16:35:58.332Z","phase":"Phase 1","brief_title":"Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia","source_id_and_acronym":"NCT05665075","lead_sponsor":"Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • QN-023a"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 12/24/2022","start_date":" 12/24/2022","primary_txt":" Primary completion: 12/24/2023","primary_completion_date":" 12/24/2023","study_txt":" Completion: 12/24/2025","study_completion_date":" 12/24/2025","last_update_posted":"2023-01-02"},{"id":"07ab1569-8076-4047-9873-382e6164c635","acronym":"","url":"https://clinicaltrials.gov/study/NCT05601466","created_at":"2022-11-03T04:55:58.967Z","updated_at":"2024-07-02T16:36:00.901Z","phase":"Phase 1","brief_title":"Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia","source_id_and_acronym":"NCT05601466","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • QN-023a"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 10/21/2025","primary_completion_date":" 10/21/2025","study_txt":" Completion: 10/21/2025","study_completion_date":" 10/21/2025","last_update_posted":"2022-11-07"},{"id":"fa138073-4631-4982-9ec7-aa34908ab4fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT05473221","created_at":"2022-07-25T20:54:41.104Z","updated_at":"2024-07-02T16:36:06.848Z","phase":"Phase 1","brief_title":"Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML","source_id_and_acronym":"NCT05473221","lead_sponsor":"Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 CAR-T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 08/02/2024","primary_completion_date":" 08/02/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2022-07-25"},{"id":"60f966ca-31c0-4b48-b372-4939f74290d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05467254","created_at":"2022-07-20T12:56:29.839Z","updated_at":"2024-07-02T16:36:07.070Z","phase":"Phase 1","brief_title":"Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML","source_id_and_acronym":"NCT05467254","lead_sponsor":"Zhejiang University","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 CAR-T • CLL1+CD33 CAR-T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 08/02/2024","primary_completion_date":" 08/02/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2022-07-20"},{"id":"e61adf06-d406-45f5-8f21-d7a2cfb82fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05445765","created_at":"2022-07-06T15:54:41.802Z","updated_at":"2024-07-02T16:36:07.720Z","phase":"Phase 1","brief_title":"Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia","source_id_and_acronym":"NCT05445765","lead_sponsor":"iCell Gene Therapeutics","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ICG165"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-07-06"},{"id":"3306e60c-4945-444d-819a-134e331e3b42","acronym":"","url":"https://clinicaltrials.gov/study/NCT03727750","created_at":"2021-01-18T18:15:55.216Z","updated_at":"2024-07-02T16:36:14.666Z","phase":"Phase 4","brief_title":"Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML","source_id_and_acronym":"NCT03727750","lead_sponsor":"Pfizer","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 04/27/2021","primary_completion_date":" 04/27/2021","study_txt":" Completion: 04/27/2021","study_completion_date":" 04/27/2021","last_update_posted":"2022-03-25"},{"id":"6d47cf58-c1e8-40cb-9336-c3af2e42c71f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05215015","created_at":"2022-02-05T18:27:41.589Z","updated_at":"2024-07-02T16:36:17.805Z","phase":"Phase 1","brief_title":"Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia","source_id_and_acronym":"NCT05215015","lead_sponsor":"Wuxi People's Hospital","biomarkers":" IL6 • TNFA • CD33 • IL2 • IL10","pipe":" | ","alterations":" CD33 positive","tags":["IL6 • TNFA • CD33 • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IBR733"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/30/2020","start_date":" 11/30/2020","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 11/30/2022","study_completion_date":" 11/30/2022","last_update_posted":"2022-01-31"},{"id":"59320b4f-78cf-4636-bc0f-1335041f19cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01020539","created_at":"2021-01-18T04:00:10.514Z","updated_at":"2024-07-02T16:36:26.842Z","phase":"Phase 1","brief_title":"Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia","source_id_and_acronym":"NCT01020539","lead_sponsor":"Columbia University","biomarkers":" FLT3 • CD33","pipe":" | ","alterations":" FLT3 mutation • CD33 positive","tags":["FLT3 • CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mylotarg (gemtuzumab ozogamicin) • fludarabine IV • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 09/11/2002","start_date":" 09/11/2002","primary_txt":" Primary completion: 07/20/2011","primary_completion_date":" 07/20/2011","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2021-08-06"}]